Stimulant Therapy for Moderately Elevated Conners Scores

Diagnostic Requirements Before Treatment

The American Academy of Child and Adolescent Psychiatry recommends obtaining a comprehensive psychiatric and medical history, including collateral information from at least two sources in different settings, to verify symptoms across contexts 1, 2
The American Academy of Child and Adolescent Psychiatry suggests documenting DSM-IV or ICD-10 criteria for ADHD with specific attention to symptom onset, chronicity, and pervasiveness across settings 1, 2
The American Academy of Child and Adolescent Psychiatry advises assessing functional impairment severity in academic/occupational, social, and family domains, with only moderate to severe impairment in at least two settings qualifying for stimulant treatment 1, 2

The American Academy of Child and Adolescent Psychiatry recommends first-line treatment with stimulant medication (methylphenidate or amphetamines) for established ADHD diagnosis with moderate-to-severe impairment, with 70-80% response rates and a strong evidence base from over 161 randomized controlled trials 2, 3
The American Academy of Child and Adolescent Psychiatry suggests starting with methylphenidate 5 mg or dextroamphetamine 2.5 mg twice daily, titrating weekly by 5-10 mg (MPH) or 2.5-5 mg (DEX/AMP) based on response 4
The American Academy of Child and Adolescent Psychiatry recommends obtaining teacher/workplace ratings using validated, age- and sex-normed instruments at baseline and after treatment to objectively document response 1

The American Academy of Child and Adolescent Psychiatry advises never prescribing stimulants based on screening scales alone, as clinical judgment about functional impairment is paramount 1, 2
The American Academy of Child and Adolescent Psychiatry suggests avoiding treatment of "subclinical" ADHD symptoms that cause only mild impairment or occur in a single setting, as the risk-benefit ratio does not favor stimulant use 1